On July 15, a landmark coalition led by the American College of Obstetricians and Gynecologists (ACOG), the Society for Women’s Health Research (SWHR), and the Women First Research Coalition (WFRC) officially introduced the National Strategy to Close the Women’s Health Gap. This ambitious and comprehensive framework serves as a direct appeal to the United States Congress, requesting a sustained investment of $20 billion over the next decade. The primary objective of this funding is to fundamentally transform the landscape of women’s health by addressing long-standing disparities in research, clinical care, and health outcomes. This initiative represents one of the most significant collective efforts in recent history to prioritize the physiological and medical needs of women, who comprise more than 50% of the American population but have historically been underserved by the medical establishment.
The strategy has garnered unprecedented support from a broad spectrum of the medical community. The Endocrine Society, along with more than 20 other professional medical organizations, patient advocacy groups, and research institutions, has formally endorsed the plan. The coalition argues that the current "health gap" is not merely a matter of scientific oversight but a systemic failure that impacts national productivity, family stability, and the overall quality of life for millions of citizens. By focusing on five key pillars—research, data, clinical care, workforce development, and policy modernization—the strategy aims to ensure that women receive evidence-based care tailored to their unique biological needs throughout every stage of their lives.
Historical Context and the Evolution of Women’s Health Advocacy
To understand the necessity of the National Strategy, it is essential to examine the historical trajectory of women’s health research in the United States. For much of the 20th century, women were largely excluded from clinical trials and medical research. This exclusion was often justified by the complexity of female hormonal cycles, which researchers claimed introduced too many variables into studies. Consequently, medical treatments, drug dosages, and diagnostic protocols were developed based on data derived primarily from male subjects, under the erroneous assumption that women were simply "smaller men."
A major turning point occurred in 1993 with the passage of the NIH Revitalization Act. This landmark legislation required the inclusion of women and minority groups in all National Institutes of Health (NIH)-funded clinical research. While the 1993 Act was a monumental step forward, advocates argue that it was only a beginning. Despite the increased presence of women in clinical trials, significant gaps remain. Many studies still fail to analyze data by sex, meaning that while women are participating, the specific ways in which treatments affect female biology are often not reported or understood.
The timeline of women’s health advocacy has moved from a fight for inclusion to a fight for specificity. In the early 2000s, organizations began pushing for the "Sex as a Biological Variable" (SABR) policy, which the NIH finally implemented in 2016. However, even with these policies in place, the National Strategy highlights that funding for conditions that exclusively or disproportionately affect women—such as endometriosis, maternal mortality, and menopause—remains disproportionately low compared to the disease burden they represent.
Supporting Data: Quantifying the Health Gap
The call for a $20 billion investment is backed by a growing body of data illustrating the economic and social costs of the women’s health gap. According to reports from the World Economic Forum and the McKinsey Health Institute, closing the gender health gap could add $1 trillion to the global economy annually by 2040. In the United States, the costs are reflected in rising maternal mortality rates, high rates of undiagnosed autoimmune diseases, and the economic impact of conditions like menopause, which can lead to decreased workforce participation.
Maternal mortality remains a critical focal point of the National Strategy. The United States currently has the highest maternal mortality rate among developed nations, with Black women being three times more likely to die from pregnancy-related causes than white women. Furthermore, research indicates that autoimmune diseases affect women at a rate of nearly 4 to 1 compared to men, yet the underlying mechanisms for this disparity are not fully understood.
The National Strategy also points to the "innovation gap." Currently, only a small fraction of venture capital and federal research funding is directed toward female-specific conditions. For instance, while endometriosis affects roughly 10% of women worldwide—a prevalence similar to diabetes—it receives a fraction of the research funding. By injecting $20 billion into the system, the coalition aims to incentivize the private sector and academic institutions to pivot toward these neglected areas of study.
The Role of Hormonal Research and the Endocrine Society’s Stance
One of the most vocal supporters of the National Strategy is the Endocrine Society, which emphasizes the critical role of hormones in every facet of female physiology. Endocrine Society President Nanette Santoro, MD, highlighted that hormones influence everything from cardiovascular health and bone density to mental health and metabolism.
"Because hormones influence nearly every aspect of women’s health, advancing research in this area has the potential to improve millions of lives," stated Dr. Santoro. "We are encouraged by this strategy’s emphasis on research, data, and clinical care and look forward to supporting efforts that accelerate progress for women nationwide."
The society argues that a deeper understanding of the endocrine system is the key to unlocking better treatments for a variety of conditions. For example, the transition into menopause is a major biological shift that affects heart health and cognitive function, yet clinical guidance for menopause management remains inconsistent. The National Strategy seeks to standardize this care through rigorous, data-driven research that accounts for hormonal fluctuations across the lifespan.
Five Key Priorities for Investment
The National Strategy recommends that the $20 billion investment be distributed across five strategic priorities designed to create a sustainable ecosystem for women’s health:
- Transformative Research Funding: Increasing the budget for the NIH and other federal agencies to specifically target female-prevalent and female-unique conditions.
- Data Standardization and Collection: Requiring that all federally funded research not only include women but also perform sex-disaggregated data analysis to identify differences in treatment efficacy and safety.
- Clinical Care Integration: Bridging the gap between laboratory discovery and the doctor’s office. This involves updating clinical guidelines to reflect the latest sex-specific research.
- Workforce Development: Investing in the training of more OB-GYNs, female-focused researchers, and specialists. This includes addressing the shortage of healthcare providers in rural and underserved areas.
- Policy and Regulatory Modernization: Updating FDA and other regulatory frameworks to ensure that medical devices and pharmaceuticals are tested for safety and efficacy specifically in female populations.
ACOG Chief Executive Officer Sandra E. Brooks, MD, MBA, FACOG, noted that the human element of this strategy is just as important as the financial one. "Closing the women’s health gap requires not only funding research, but also investment in the people who conduct that research and those who translate research findings and discoveries into better patient care," she said.
Broader Impact and Implications for the Future
The implications of the National Strategy extend far beyond the walls of the clinic. By addressing the health gap, the coalition believes that the United States can see a "ripple effect" of positive outcomes. Improved maternal health leads to better child health outcomes; better management of chronic conditions in women leads to more stable families and communities; and a healthier female workforce drives national economic growth.
The strategy also carries significant weight for health equity. By emphasizing data and clinical care across "every stage of life," the framework explicitly acknowledges that women’s health is not limited to reproductive years. It encompasses pediatric health, adolescent development, the complexities of aging, and the unique challenges faced by women of color and those in marginalized communities.
Kathryn Schubert, MPP, CAE, President and CEO of the Society for Women’s Health Research, emphasized the long-term vision of the proposal. "The women’s health gap has persisted for far too long," Schubert said. "This strategy offers Congress a roadmap to improve health outcomes, drive innovation, and build a healthier future for women, families, and communities."
A Coalition of Support
The strength of the National Strategy lies in its broad-based endorsement. The list of supporting organizations includes major players such as the American Heart Association, the Alzheimer’s Association (Women’s Alzheimer’s Movement), and the Arthritis Foundation. These groups recognize that diseases like heart disease and Alzheimer’s manifest differently in women, requiring a specialized approach that the National Strategy promises to provide.
Other endorsers include:
- Alliance for Aging Research
- Black Women’s Health Imperative
- Lupus Foundation of America
- March of Dimes
- National MS Society
- Prevent Blindness
- The Menopause Society
As the proposal moves to Congress, the coalition is urging lawmakers to view the $20 billion request not as an expense, but as a high-yield investment in the nation’s infrastructure. With the framework now public, the next steps will involve legislative drafting and advocacy efforts to secure the necessary appropriations.
The National Strategy to Close the Women’s Health Gap represents a definitive rejection of the "one-size-fits-all" approach to medicine. It is a call for a future where medical science is as diverse as the population it serves, ensuring that half of the nation is no longer left in the shadows of clinical discovery. By strengthening research, modernizing policy, and investing in the healthcare workforce, the United States has the opportunity to lead the world in sex-specific medicine and provide women with the high-quality, evidence-based care they have long deserved.
